A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Trial Profile

A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Naftifine (Primary)
  • Indications Tinea pedis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merz Pharma
  • Most Recent Events

    • 17 Oct 2013 New trial record
    • 10 Oct 2013 Primary endpoint 'Clinical-cure-rate' has been met.
    • 10 Oct 2013 Naftifine 2% gel was approved for interdigital-type tinea pedis based on results from two pivotal US-based trials, including this trial, according to a Merz North America media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top